Although there are no reports of a direct implication of the c-Jun protein in T2DM therapeutics, the activating kinase, c-Jun N-terminal kinase (JNK), has been linked to insulin resistance, dysfunctional β-cells, and the transition from obesity to DM [51]. The gene discussed is JUN; the disease is type 2 diabetes mellitus.